首页> 外文OA文献 >Combining Parasite Lactate Dehydrogenase-Based and Histidine-Rich Protein 2-Based Rapid Tests To Improve Specificity for Diagnosis of Malaria Due to Plasmodium knowlesi and Other Plasmodium Species in Sabah, Malaysia
【2h】

Combining Parasite Lactate Dehydrogenase-Based and Histidine-Rich Protein 2-Based Rapid Tests To Improve Specificity for Diagnosis of Malaria Due to Plasmodium knowlesi and Other Plasmodium Species in Sabah, Malaysia

机译:结合基于寄生虫乳酸脱氢酶和富含组氨酸的蛋白质2的快速测试,以提高对马来西亚沙巴的诺氏疟原虫和其他疟原虫种类引起的疟疾诊断的特异性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Plasmodium knowlesi causes severe and fatal malaria in Malaysia. Microscopic misdiagnosis is common and may delay appropriate treatment. P. knowlesi can cross-react with “species-specific” parasite lactate dehydrogenase (pLDH) monoclonal antibodies used in rapid diagnostic tests (RDTs) to detect P. falciparum and P. vivax. At one tertiary-care hospital and two district hospitals in Sabah, we prospectively evaluated two combination RDTs for malaria diagnosis by using both a pan-Plasmodium-pLDH (pan-pLDH)/P. falciparum-specific-pLDH (Pf-pLDH) RDT (OptiMAL-IT) and a non-P. falciparum VOM-pLDH/Pf-HRP2 RDT (CareStart). Differential cross-reactivity among these combinations was hypothesized to differentiate P. knowlesi from other Plasmodium monoinfections. Among 323 patients with PCR-confirmed P. knowlesi (n = 193), P. falciparum (n = 93), and P. vivax (n = 37) monoinfections, the VOM-pLDH individual component had the highest sensitivity for nonsevere (35%; 95% confidence interval [CI], 27 to 43%) and severe (92%; CI, 81 to 100%) P. knowlesi malaria. CareStart demonstrated a P. knowlesi sensitivity of 42% (CI, 34 to 49%) and specificity of 74% (CI, 65 to 82%), a P. vivax sensitivity of 83% (CI, 66 to 93%) and specificity of 71% (CI, 65 to 76%), and a P. falciparum sensitivity of 97% (CI, 90 to 99%) and specificity of 99% (CI, 97 to 100%). OptiMAL-IT demonstrated a P. knowlesi sensitivity of 32% (CI, 25 to 39%) and specificity of 21% (CI, 15 to 29%), a P. vivax sensitivity of 60% (CI, 42 to 75%) and specificity of 97% (CI, 94 to 99%), and a P. falciparum sensitivity of 82% (CI, 72 to 89%) and specificity of 39% (CI, 33 to 46%). The combination of CareStart plus OptiMAL-IT for P. knowlesi using predefined criteria gave a sensitivity of 25% (CI, 19 to 32%) and specificity of 97% (CI, 92 to 99%). Combining two RDT combinations was highly specific for P. knowlesi malaria diagnosis; however, sensitivity was poor. The specificity of pLDH RDTs was decreased for P. vivax and P. falciparum because of P. knowlesi cross-reactivity and cautions against their use alone in areas where P. knowlesi malaria is endemic. Sensitive P. knowlesi-specific RDTs and/or alternative molecular diagnostic tools are needed in areas where P. knowlesi malaria is endemic.
机译:恶性疟原虫在马来西亚引起严重和致命的疟疾。显微镜下的误诊很常见,可能会延迟适当的治疗。诺氏疟原虫可以与快速诊断测试(RDT)中使用的“物种特异性”寄生虫乳酸脱氢酶(pLDH)单克隆抗体发生交叉反应,以检测恶性疟原虫和间日疟原虫。在沙巴州的一家三级医院和两家地区医院,我们通过使用全Plasmodium-pLDH(pan-pLDH)/ P前瞻性评估了两种组合的RDT用于疟疾诊断。恶性血浆特异性pLDH(Pf-pLDH)RDT(OptiMAL-IT)和非P。恶性肿瘤VOM-pLDH / Pf-HRP2 RDT(CareStart)。假设这些组合之间的交叉反应性不同,以区分诺氏疟原虫与其他疟原虫单感染。在323例经PCR确诊的诺氏疟原虫(n = 193),恶性疟原虫(n = 93)和间日疟原虫(n = 37)单一感染中,VOM-pLDH单个成分对非严重感染的敏感性最高(35) %; 95%置信区间[CI]为27至43%)和严重(92%; CI为81至100%)诺氏疟疾。 CareStart证明诺氏疟原虫敏感性为42%(CI,34至49%)和特异性为74%(CI,65至82%),间日疟原虫敏感性为83%(CI,66至93%)和特异性恶性疟原虫的敏感性为71%(CI为65至76%),恶性疟原虫敏感性为97%(CI为90至99%),特异性为99%(CI为97至100%)。 OptiMAL-IT证明诺氏疟原虫敏感性为32%(CI,25至39%)和特异性为21%(CI,15至29%),间日疟原虫敏感性为60%(CI,42至75%)特异性为97%(CI为94至99%),恶性疟原虫敏感性为82%(CI为72至89%)和特异性为39%(CI为33至46%)。使用预先定义的标准,将CareStart加上OptiMAL-IT用于诺氏假单胞菌的敏感性为25%(CI,19至32%),特异性为97%(CI,92至99%)。结合两种RDT组合对于诺氏疟原虫疟疾诊断具有高度特异性。但是,敏感性差。由于间日疟原虫交叉反应,间日疟原虫和恶性疟原虫的pLDH RDTs特异性降低,并警告不要在诺氏疟原虫疟疾流行地区单独使用它们。在诺氏疟原虫疟疾流行地区需要灵敏的诺氏疟原虫特有的RDT和/或替代性分子诊断工具。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号